Comparison 2. Carbetocin vs Placebo or no treatment.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2 PPH >= 1000 mL	1	50	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
3 Blood transfusion	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
4 Severe maternal morbidity: intensive care admissions	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
5 Severe maternal morbidity: shock	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
6 PPH >= 500 mL	1	50	Risk Ratio (IV, Random, 95% CI)	0.75 [0.30, 1.85]
7 Additional uterotonics	2	169	Risk Ratio (IV, Random, 95% CI)	0.19 [0.12, 0.32]
8 Blood loss	1	50	Mean Difference (IV, Random, 95% CI)	‐274.0 [‐591.60, 43.60]
9 Change in haemoglobin	1	50	Mean Difference (IV, Random, 95% CI)	‐3.40 [‐7.23, 0.43]
10 Breastfeeding	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
11 Nausea	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
12 Vomiting	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
13 Headache	1	50	Risk Ratio (IV, Random, 95% CI)	5.0 [0.25, 99.16]
14 Abdominal pain	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
15 Hypertension	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
16 Shivering	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
17 Fever	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
18 Diarrhoea	0	0	Risk Ratio (IV, Random, 95% CI)	0.0 [0.0, 0.0]
19 Maternal well‐being	0		Risk Ratio (IV, Random, 95% CI)	Totals not selected
20 Maternal satisfaction	0		Risk Ratio (IV, Random, 95% CI)	Totals not selected